Similar articles

• Benazepril for advanced chronic renal insufficiency.

  Jaber BL, Madias NE. Jaber BL, et al. N Engl J Med. 2006 Apr 6;354(14):1530-1; author reply 1530-1. N Engl J Med. 2006. PMID: 16602150 No abstract available.
• Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.

  Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Maschio G, et al. N Engl J Med. 1996 Apr 11;334(15):939-45. doi: 10.1056/NEJM199604113341502. N Engl J Med. 1996. PMID: 8596594 Clinical Trial.
• Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency.

  Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, Guo ZJ, Jiang JP. Hou FF, et al. J Am Soc Nephrol. 2007 Jun;18(6):1889-98. doi: 10.1681/ASN.2006121372. Epub 2007 May 9. J Am Soc Nephrol. 2007. PMID: 17494885 Clinical Trial.
• Angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers after renal transplantation.

  Morath C, Schmied B, Mehrabi A, Weitz J, Schmidt J, Werner J, Buchler MW, Morcos M, Nawroth PP, Schwenger V, Doehler B, Opelz G, Zeier M. Morath C, et al. Clin Transplant. 2009 Dec;23 Suppl 21:33-6. doi: 10.1111/j.1399-0012.2009.01107.x. Clin Transplant. 2009. PMID: 19930314 Review.
• The use of ACE inhibitors and ARBs in severe chronic kidney disease: point-counterpoint.

  Creamer LM, Ryan J. Creamer LM, et al. CANNT J. 2008 Oct-Dec;18(4):46-8. CANNT J. 2008. PMID: 19175194 Review. No abstract available.